The platinum-free interval is the most important predictive factor of a response to subsequent lines of chemotherapy and the most important prognostic factor for progression-free and overall survival in patients with recurrent epithelial ovarian cancer. A nonplatinum regimen is generally considered the most appropriate approach when the disease recurs very early after the end of chemotherapy, whereas platinum-based chemotherapy is usually adopted when the platinum-free interval exceeds 12 months. However, the therapeutic management of patients with intermediate sensitivity (ie, when the relapse occurs between 6 and 12 months) remains debatable. Preclinical and clinical data suggest that the extension of platinum-free interval (using a nonplatinum-based regimen) might restore platinum sensitivity, thus allowing survival improvement. The objective of this review was to critically analyze preclinical and clinical evidences supporting this hypothesis. Cancer 2017;123:3450-9.
INTRODUCTION
Conventionally, recurrent ovarian cancer has been classified on the basis of platinum-free interval (PFI), which is calculated from the last cycle of platinum-containing treatment to the time of disease progression. 1 When patients progress during platinum-containing regimens or within 4 weeks after the last platinum dose, their disease is considered refractory. When progression occurs within 6 months from the last platinum administration, they are said to harbor platinum-resistant disease; whereas, if their disease progresses after a PFI of at least 12 months, then the disease is considered platinum sensitive (PS).
Approximately 20% of patients will experience a relapse within 6 to 12 months, a category defined by some as partially platinum sensitive (PPS), because their treatment outcome lies in between that of patients who have platinumresistant and PS disease. Although clinical evidence indicates that platinum-based chemotherapy can be effectively readministered to patients with PS recurrence, re-challenge with platinum-containing regimens in PPS recurrences remains debatable.
Preclinical and clinical data suggest that extending the PFI using a nonplatinum-containing regimen may be associated with an improved clinical benefit through the restoration of platinum sensitivity, thus leading to more effective retreatment with a platinum-containing regimen at progression. The main objective of this review was to critically explore the most important evidence supporting this hypothesis.
PFI AND DEFINING PLATINUM SENSITIVITY
The historic classification of recurrent ovarian cancer according to PFI 1 has recently been criticized for various reasons. Platinum sensitivity has been defined arbitrarily based on observational studies and a probabilistic partition with the likelihood of response being a continuous variable. It can be heavily influenced by the timing of follow-up visits and the use of cancer antigen 125 as a trigger leading to further imaging examinations and modalities that have changed significantly over time. Furthermore, improvements in surgical cytoreduction techniques and the introduction of biologic agents as maintenance therapy may have modified the natural course of disease. Finally, the definition of platinum sensitivity only applies to chemotherapy, because no similar correlation has been demonstrated for other agents currently used in clinical practice.
The last Gynecologic Cancer Intergroup consensus conference proposed to replace PFI with the term therapyfree interval (TFI), dividing it into platinum-TFI (TFIp), nonplatinum-TFI (TFInp), and biologic agent-TFI (TFIb) to better define different trial populations. 2 However, to date, most clinical trials in recurrent disease, including those reported in the current literature review, applied the 2011 Gynecologic Cancer Intergroup categorization. 1 
PLATINUM-BASED STRATEGIES IN PS RECURRENT DISEASE
In women with PS ovarian cancer, the use of a platinumbased combination is supported by several randomized clinical trials (Table 1) . [3] [4] [5] [6] [7] [8] [9] A meta-analysis of 5 randomized clinical trials [3] [4] [5] [6] [7] published in 2013 demonstrated that the use of platinum-based combination chemotherapy improved both overall survival (OS) and progression-free survival (PFS) compared with platinum alone. 10 The Calypso trial and a Cochrane meta-analysis concluded that, in PS disease, carboplatin combined with pegylated liposomal doxorubicin (PLD) was more effective and better tolerated than other combinations, suggesting that it should be considered as the first treatment choice for women who have PS disease.
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Because conventional chemotherapy is unable to fully eradicate the disease, other therapies targeting specific molecular pathways have been investigated.
Clinical evidence indicates that, in patients with PS disease, the use of an antivascular epidermal growth factor monoclonal antibody (bevacizumab) improves PFS in association with carboplatin/gemcitabine and as maintenance treatment (12.4 vs 8.4 months, respectively; P < .0001) compared with carboplatin/gemcitabine alone. 9 Although its use is only associated with a small increase in PFS 12 without improvement in OS, 13 bevacizumab has been approved in different countries in conjunction with carboplatin/gemcitabine for the treatment of PS recurrent disease.
Moreover, because ovarian cancer is highly associated with germ-line or somatic mutations in homologous recombination repair pathways, another possible target strategy consists of using different poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. A phase 2 randomized clinical trial demonstrated a significant improvement in PFS for patients with PS recurrent ovarian cancer who received the PARP inhibitor olaparib as maintenance treatment after an initial response to platinum-based chemotherapy compared with placebo (8.4 vs 4.8 months; P < .0001) 14 . The greatest PFS benefit with this therapy was achieved in patients who had Breast Related Cancer Antigens 1 and 2 (BRCA1/2) gene mutations. 15 Although an OS advantage was observed in all patients, the difference was not statistically significant. 16 These data have led to the approval of olaparib in Europe as maintenance treatment for patients with PS BRCA-mutated recurrent disease.
Niraparib, a highly selective inhibitor of PARP1/ PARP2, prolonged PFS when used as maintenance therapy for women who had PS recurrences with and without germline BRCA mutations, although the greatest benefit was obtained in those with germline mutations (21.0 vs 5.5 months; P < .0001). 17 These data have to the approval of niraparib by the US Food and Drugs Administration as maintenance therapy for patients with PS recurrence, independent of BRCA status. Other studies are currently examining the use of different PARP inhibitors alone or in combination for recurrent ovarian cancer.
PLATINUM-FREE STRATEGIES IN PS RECURRENT DISEASE
Because PFI is the most important predictive factor for response to platinum retreatment and the most important prognostic factor for PFS and OS, there is increasing interest in strategies to extend the PFI, mainly in PPS disease. Moreover, even if it is quite effective, platinum rechallenge may be associated with significant clinical side effects, such as hypersensitivity reactions (particularly in patients who receive multiple courses of carboplatin), residual neuropathy, and severe cumulative myelosuppression. For these reasons, other strategies, including nonplatinum-containing regimens, have been tested. Table 2 reports clinical studies that tested platinumfree strategies in PS disease. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] It is noteworthy that PLD produced more benefit in the PPS subgroup than in patients with a PFI >12 months. 19, 20 Trabectedin as single agent has been identified as active second-line and third-line therapy in patients with recurrent ovarian cancer in various studies. 23, [26] [27] [28] Moreover, it has been demonstrated that this compound is able to induce biologic changes in cancer cells and in the tumor microenvironment that may favor a subsequent response to platinum compounds. However, these peculiar mechanisms, as highlighted in the sections below, have been observed in preclinical systems, but no evidence exists that they are reproduced in the clinic. Therefore, trabectedin is discussed in the current review as a model drug to test the hypothesis that modifying the biologic properties of the tumor could be a feasible way to enhance subsequent treatment with platinum compounds. In this context, it seems legitimate to speculate that, if resistance to platinum compounds is related at least in part to epigenetic mechanisms, then it may be possible to reverse platinum resistance by using agents that modify the methylation status of crucial genes, such as azacytidine, or that inhibit the posttranslational modification of histones, such as histone deacetylase, or the binding of histones to regulatory DNA sequences, such as bromodomain inhibitors. However, to our knowledge, trabectedin is the only compound for which convincing in vivo experimental evidence of this platinumrestoration mechanism is available. Also, for the potential effects of inhibitors of immune checkpoints, no clinical data are available to justify their use in patients with recurrent disease, although it has been reported that ovarian cancer is highly immunogenic. 31 RESTORING PLATINUM SENSITIVITY Some authors tested the effect of PFI extension through intercalation of nonplatinum therapy on further treatments and survival, as mentioned above. However, few studies reported separate results for the PPS patient population, and the majority of their data are from unplanned, retrospective subset analyses. 
Preclinical Data
Mechanisms of sensitivity/resistance to platinum compounds Platinum compounds (PCs) bind DNA, thus forming interstrand and intrastrand cross-links as well as DNAprotein crosslinks and various monoadducts. The selectivity of PCs is mainly related to the inefficient DNA repair and DNA damage response of cancer cells compared with normal cells. The peculiar susceptibility of some tumors to PCs seems to be mainly related to defects in DNA repair mechanisms. Other biologic factors may also play a role and are related not only to DNA repair but also to DNA damage involving the activation of checkpoints of the cell cycle as well as proapoptotic and antiapoptotic factors. It should not be ignored that the therapeutic effects of chemotherapy depend not only on the drug sensitivity of cancer cells but also on their effects on the tumor stroma and on the normal cells infiltrating the tumor. The tumor microenvironment not only influences the aggressiveness and the metastatic potential of malignant tumors but also modulates the level of sensitivity to therapy and the ability to evade the immune system. 32 Cancer cell resistance to PCs may be attributed to low drug retention caused by decreased cellular uptake because of decreased expression of copper transporters or organic cation transporters or increased drug efflux. Moreover, rapid binding of the active site by glutathione or metallothioneins may prevent their interaction with DNA. Also, increased DNA repair efficiency (with homologous recombination and nucleotide excision repair [NER] being the main players) or epigenetic mechanisms, including changes in methylation status, may be associated with platinum resistance. Finally, micro-RNA expression, transcription factors, and small guanosine triphosphatases; inactivation of apoptotic pathways; and activation of the epithelial mesenchymal transition (EMT) 33 are also landmarks of resistance. Recent studies with next-generation DNA sequencing have demonstrated a very high spatial and temporal heterogeneity of the mutational profile of ovarian cancer, 34, 35 particularly after treatment, because of the high genomic instability of this neoplasm. 36 PCs induce the destruction of cancer cells that are PS, and the surviving clones presumably are less sensitive or more resistant. Thus, the degree of the response and the duration of PFI will depend on the proportion of cells that are killed by PCs and by the growth rate of the resistant clones that persist after therapy; the latter also depend on host factors and features of the tumor microenvironment. However, resistant tumors are highly heterogeneous and genomically unstable, resulting in a variety of subclones with different degrees of sensitivity to platinum or other drugs.
Therefore, it is reasonable to assume that, upon platinum re-challenge, a longer PFI will be associated with a greater probability of achieving higher tumor responses and longer PFS and OS. Moreover, drugs available as alternative to PCs should be selected, taking into account their mechanism of action and lack of cross-resistance with PCs. Although the mutational profile is certainly of great importance in relation to cancer cell sensitivity to PCs and many other drugs, it seems plausible to hypothesize that there are also epigenetic mechanisms of resistance in ovarian cancer. These might be responsible for the EMT mechanism, consisting of a shift in the epithelial phenotype toward a mesenchymal 1 that is associated with stemness features and refractoriness to treatment. 37 In this respect, it is worth mentioning recent studies in which the expression of a single micro-RNA, such as miR181a, was associated with a rapid tumor relapse after carboplatin/paclitaxel therapy. 38 The mechanism of resistance appears to be related to the ability of miR181a to down-regulate SMAD family member 7 (SMAD7), which is an inhibitor of transforming growth factor b (TGF-b). By determining both mir181a and phosphorylated SMAD2, as a read out of TGF-b activation, it is possible to predict ovarian cancer resistance, low PFS, and short survival. 37 Most probably, not only cancer cells but also inflammatory cells infiltrating the tumor are involved in the activation of TGF-b, with consequent tissue modification, which acquires a mesenchymal phenotype. 36 These observations should force us to remember that the strategies used to counteract resistance to platinum-based strategies should also include therapies aimed at modifying the tumor microenvironment.
Why trabectedin?
Trabectedin (ET-743; Yondelis, Madrid, Spain) is a marine-derived tetrahydroisoquinoline alkaloid with antitumor activity. This agent selectively depletes blood monocytes and tumor-associated macrophages in tumor-bearing mice and in patients with soft tissue sarcoma and ovarian cancer by blocking the cell cycle, inducing p53-independent apoptosis, and interfering with transcription-regulatory pathways. The activity of trabectedin is probably because of its ability to act as a modifier of the tumor microenvironment modifier [39] [40] [41] [42] (Fig. 1) . The rationale behind the choice of trabectedin is based mainly on some preclinical mechanistic studies that made this drug very attractive in this context. Moreover, the combination of trabectedin with PLD seems of particular interest. Both drugs penetrate and are retained within cells using transport systems different from those used by platinum compounds and thus should not share some of the known resistance mechanisms. In addition, preclinical studies suggest that the combination of trabectedin and PLD can be effective in increasing sensitivity to platinum compounds given sequentially.
The interaction of trabectedin with DNA is very different from that of other drugs. 39 It binds in the minor groove of DNA, forming adducts at the N2 position of guanines and not at N7. Conversely, the N7 position of guanines is the preferential site of binding for most DNAinteracting drugs, including platinum derivatives. Although both trabectedin and platinum compounds are particularly effective against cells deficient in homologous recombination, the pattern of sensitivity of cells with other DNA repair defects appear to be very different. In Review Article particular, cells that are deficient in NER-a pathway involved in the repair of DNA bulky adducts caused by platinum compounds-are very sensitive to these drugs, whereas they are partially resistant to trabectedin. 43, 44 It has been demonstrated both in vitro and in vivo 45, 46 that cancer cell lines made resistant to trabectedin by prolonged drug exposure become more sensitive to ultraviolet light and to platinum compounds. 47 The reason for this collateral sensitivity is the occurrence of defects in the NER machinery because of mutations or lack of expression of genes involved in this pathway, such as xeroderma pigmentosum type G or type F (XPG or XPF), and consequent impairment of the repair of platinum-induced DNA adducts. These data were recently confirmed by Englinger et al. 48 Those authors speculated that the transient downregulation of cullin A4 (CUL4A), which is involved in NER mechanisms, caused by trabectedin in colon cancer cell lines enhances the sensitivity cisplatin. Although these data were obtained in preclinical systems, their consistency suggests that a similar phenomenon also can occur in the clinic.
The rationale behind the sequential treatment is schematically highlighted in Figure 2 , which indicates that trabectedin can induce the selection of cell clones that are hypersensitive to platinum compounds because of their NER deficiency. Treatment with trabectedin probably selects out cancer cell clones that are NER-deficient and thus hypersensitive to PCs. Therefore, trabectedin should enhance the subsequent antitumor activity of platinum treatment.
Another peculiar feature of the mechanism of action of trabectedin is that some of its antitumor properties are caused not by a direct effect on cancer cells but by an indirect effect on the tumor microenvironment. In many experimental models, the drug strongly reduces the number and function of tumor-associated macrophages, 42 with decreased production of inflammatory cytokines and of angiogenic, growth, and immunosuppressive factors responsible for the resistance to proapoptotic treatments; and evasion from the adaptive immune response and the induction of EMT, reportedly associated with resistance to therapies and short survival in patients with ovarian cancer. These observations, which have been confirmed in several preclinical systems and corroborated by the finding that trabectedin modifies the transcription regulation of genes involved in inflammation, like interleukin 6, and in EMT, such as q-guanosine triphosphatases, 49 could also play a role in improving the effectiveness of sequential treatment with trabectedin followed by PCs.
The role of the tumor microenvironment in determining therapy effectiveness and outcome, as emphasized above, is gaining more and more importance. In this context, the use of a drug like trabectedin, for which there is evidence that it acts as a modulator in the tumor microenvironment, seems very attractive. 
Clinical data
Because synergistic activity has been demonstrated in vitro when combining trabectedin with PLD, a randomized, multicenter phase 3 trial (OVA-301) tested this regimen versus PLD alone in patients with recurrent ovarian cancer. 24 In that trial, the median PFS was 7.3 months for trabectedin plus PLD versus 5.8 months with PLD alone (P 5 .0190) in the whole population. It is noteworthy that the greatest benefit was observed in patients who had PS recurrent ovarian cancer. The study also demonstrated an acceptable safety profile and, most importantly, the absence of typical platinum toxicities (neurotoxicity and hypersensitivity reactions). Thus, trabectedin in combination with PLD has been approved in Europe, Canada, and other regions of the world for use in PS recurrent ovarian cancer, but it is not available in the United States.
In particular, the US Food and Drugs Administration has pointed out that the combination produced more toxicities than doxorubicin alone and had a higher incidence of hematologic and cardiac adverse events, thus calling into question whether the increase in PFS at a cost of additional toxicity was a sufficient benefit for approval. However, a retrospective subgroup analysis from the OVA-301 study 50 revealed an improvement in OS 25 in patients with PPS recurrent disease who received treatment with trabectedin/PLD.
A detailed analysis of subsequent therapies and survival outcomes in the overall OVA-301 population and in the subsets according to platinum sensitivity suggested that subsequent platinum therapy was delayed by a median of 4 months (hazard ratio, 0.61; P 5 .0203) in the PPS population that received trabectedin/PLD; the OS after platinum-based therapy as the first subsequent line was significantly extended by a median of 8.7 months after trabectedin/PLD compared with PLD alone (18.6 vs 9.9 months; hazard ratio, 0.54; P 5 .0169). 51 Consequently, the median OS of the patients with PPS recurrent ovarian cancer who received platinum as the first subsequent therapy was 27.7 months for trabectedin/PLD versus 18.7 months for PLD alone. 52 Recently, at the 2016 American Society for Clinical Oncology annual meeting, Pignata et al reported results from the Multicenter Italian Trials in Ovarian Cancer-8 (MITO-8) study, 30 a phase 3, international, multicenter, randomized trial that compared platinum-based chemotherapy versus nonplatinum-based chemotherapy in patients with PPS recurrent ovarian cancer after previous platinum-based chemotherapy. OS was the primary endpoints; whereas PFS, PFS after the second treatment (PFS2), global toxicity, the overall response rate, and quality of life were the secondary endpoints. A postprogression crossover after the first treatment was required in both arms. Figure 2 . This is an illustration of the rationale for the sequential administration of trabectedin followed by platinum compounds. NER indicates nucleotide excision repair.
The trial was stopped prematurely because of slow recruitment with only 215 patients having been randomized into the experimental arm (n 5 107) and the standard arm (n 5 108). The median PFI before randomization was 8 months for both groups. In the experimental arm, the median time from randomization to the start of platinum-based chemotherapy was 7.8 versus 0.01 months (interquartile range, 3.7-13.3 vs 0.01-0.15 months). PFS was not statistically different; and OS, the primary established endpoint, was not improved in the experimental arm. Conversely, PFS2 was significantly longer in patients who were randomized to receive platinum-based chemotherapy (16.4 vs 12.8 months; P 5 .025).
The MITO-8 trial investigators concluded that prolonging the PFI by introducing a nonplatinum regimen did not improve efficacy outcomes in patients with PPS recurrent ovarian cancer. However, it is important to underline some limitations of their study. The trial started recruiting patients in February 2009; however, in August 2011, the enrollment was temporarily suspended because of PLD shortage. For this reason, in April 2012, an amendment was introduced to allow the use of other nonplatinum-based chemotherapies, such as topotecan and gemcitabine. This led to the existence of different patient populations in the trial: those with a long observation time from the first phase of the trial and those with a rather short second phase after the trial was resumed. Therefore, the enrolled patients were not homogenously distributed. The enrollment was closed prematurely because of slow accrual on October 2015.
The final analysis was performed in March 2016 (with 141 events in 215 enrolled patients, instead of the planned 193 events in of 253 patients, following Independent Data Monitoring Committee advice), thus lacking the power to demonstrate a difference in the primary endpoint (OS). The authors reported a statistically significant difference in PFS2, a secondary endpoint parameter that was not included in the original study design, which brings us back to a time when the definition of this parameter was unknown. In addition to these methodological observations, it has to be underscored that only single agents were allowed as nonplatinum treatments in the MITO-8 study, and PLD monotherapy was the most commonly used regimen.
On the basis of results from the OVA-301 trial, the nonplatinum agent used in MITO-8 was not the most appropriate with which to test the hypothesis of PFI prolongation, because it already had demonstrated inferior efficacy compared with combined trabectedin/PLD in the OVA-301 study. Results from MITO-8 may lead to the conclusion that PLD followed by platinum does not improve outcomes, but we are currently unable to make any conclusions about the sequential effects of combination therapy like trabectedin/PLD.
CONCLUSION
In patients with PPS recurrent disease, the use of a platinum-free therapeutic strategy may still represent a valid option. Unquestionable advantages of this therapeutic strategy include the potential absence of typical platinum toxicities, ie, hypersensitivity reactions and further neurotoxicity. Preclinical studies demonstrated that the use of a nonplatinum agent like trabectedin may restore platinum sensitivity by selecting cancer cells that are more responsive to platinum or by modifying the microenvironment. Moreover, a retrospective subgroup analysis from the OVA-301 study supported the hypothesis that trabectedin/PLD in patients with PPS disease followed by platinum re-challenge could obtain better survival than PLD monotherapy, probably restoring the platinum sensitivity. 51 These considerations provide clinical rationale for the sequential use of trabectedin/PLD and platinum compounds in PPS recurrent ovarian cancer, indicating that this combination is potentially the most effective for this scope.
Results from the MITO-8 study, which failed to demonstrate the potential benefit of sequential platinumfree monotherapies and platinum regimens in PPS disease, are not conclusive, particularly considering that the nonplatinum regimen received by most patients (ie, PLD alone) already was considered to be inferior to trabectedin/PLD, according to the OVA-301 results.
Because data supporting the hypothesis of platinum sensitivity restoration through the intercalation of platinum-free regimens like trabectedin/PLD are mostly derived from preclinical studies or retrospective subgroup analyses, prospective validation is urgently needed. The objective of the ongoing phase 3 International Randomized Study in Patients With Ovarian Cancer (INO-VATYON) trial is to demonstrate that the prolongation of PFI with trabectedin/PLD improves OS in patients affected by PPS relapse. That study is only enrolling patients who have recurrent PPS ovarian cancer after firstline or second-line platinum treatment. The patients are randomized 1:1 to receive either carboplatin/PLD or trabectedin/PLD until they experience disease progression. At the onset of subsequent progression, patients who received carboplatin/PLD can receive subsequent therapy at the investigator's discretion, whereas patients who received trabectedin/PLD must receive platinum rechallenge (unless refused by the patient). The recruitment is currently ongoing and involves approximately 140 European centers (clinicaltrials.gov identifier NCT01379989). 53 In summary, current clinical evidence can neither support nor deny the benefit of extending PFI in patients with recurrent ovarian cancer. Results from the INO-VATYON trial hopefully will clarify some of the open questions on this topic.
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